Introduction: The Safety Pharmacology Society (SPS) has conducted a survey of its membership to identify industry practices related to testing considered in the Comprehensive In vitro Proarrhythmia Assay (CiPA). Methods: Survey topics included nonclinical approaches to address proarrhythmia issues, conduct of in silico studies, in vitro ion channel testing methods used, drugs used as positive controls during the conduct of cardiac ion channel studies, types of arrhythmias observed in non-clinical studies and use of the anticipated CiPA ion channel assay.
A C C E P T E D M A N U S C R I P T
ACCEPTED MANUSCRIPT

Introduction
A need to seek understanding of mechanisms leading to drug-induced arrhythmias, with a view to better predicting drug-induced proarrhythmia with fewer false positives, has resulted in the development of the comprehensive in vitro proarrhythmia (CiPA) assay (Huang et al., 2016) .
Several biomarkers of ventricular repolarization-associated proarrhythmia risk have been considered in drug safety testing over the last few decades including QT prolongation (Stramba-Badiale et al., 1997; Authier et al., 2010) , QT dispersion (Day et al., 1990) , early afterdepolarizations (Cranefield & Aronson, 1988) and TRIaD (triangulation, reverse usedependence, instability and dispersion of repolarization) (Hondeghem et al., 2001 , Lawrence et al., 2008 . Advocating the use of multiple in vitro ion channels in drug safety evaluation has emerged as an important strategy to assess the proarrhythmia liability of drug candidates during early stages of development (Kramer et al., 2013) . While cell lines with stable heterologously expressed ion channels have been used as testing tools for decades, an increasing interest in the validation and application of human stem cell derived cardiomyocytes for proarrhythmia risk assessment is apparent (Guo et al., 2013; Navarrete et al., 2013; Qu et al., 2013; Qu et al., 2015; Himmel, 2013; Kirby et al., 2016) . Nonetheless, several factors have been shown to modulate ion channel voltage clamp study results (e.g., IC 50 values) including the experimental temperature, the physicochemical nature of the drug studied, the voltage protocol used and whether the drug is actively perfused or static in the experimental chamber (Luo & Guthrie, 2005) . Thus, numerous modifications have been proposed to optimize manual and automated patch clamp studies (Hamill et al., 1981; Wakefield et al., 2002; Lepple-Wienhues et al., 2003; Sigworth & Klemic, 2005; Brüggemann et al., 2006; Polonchuk, 2012; Comley, 2014; Obergrussberger et al., 2015) . As an unfortunate consequence, a lack of consistency in testing protocols and study designs is present across laboratories within the pharmaceutical industry and CROs. Yet, nonclinical models for assessing proarrhythmia liability remain the cornerstone of regulatory drug safety testing and establishing best practices and careful evaluation of the translational value of the data obtained remains a priority (Hammond et al., 2001; Redfern et al., 2003) . Since their inception, in silico models have also gained considerable complexity regarding their ability to generate cardiac action potentials since they integrate species differences with respect to ion channel profiles with in vitro data (Mirams et al., 2011; O'Hara & Rudy, 2012; Okada et al., 2015; Rodriguez et al., 2015) . In the clinical arena, novel approaches to replace standard thorough QT (TQT) studies have been developed and are being implemented for use in marketing authorization submissions (Shah et al., 2016; Cavero et al., 2016) . More recently, dissection of the T wave into early and late phases of repolarization A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT Authier et al 2016 JPTM 2/16/2017 4 (Johannesen et al., 2014; Vicente et al., 2015) has enabled a mechanistic evaluation of the proarrhythmia liability of drugs using clinical ECG data. Thus, proarrhythmia liability assessment is advancing at an accelerated pace from application of in silico modeling to clinical safety testing. As the regulatory paradigm for proarrhythmia liability assessment is evolving (Vincente et al., 2016) , reviewing current testing practices as they relate to drug development was undertaken by the SPS and the results are summarized herein.
Methods
This survey was distributed by the SPS to 887 safety pharmacologists, toxicologists and pharmacologists working globally in the pharmaceutical industry, at CROs, regulatory agencies, academia or the technology provider industry. Survey topics included (a) nonclinical approaches to address proarrhythmia issues, (b) conduct of in silico studies, (c) in vitro ion channel testing methods used, (d) drugs used as positive controls during the conduct of cardiac ion channel studies, (e) types of arrhythmias observed in non-clinical studies and (f) use of the anticipated CiPA ion channel assay. Survey questions are reported in the results section together with the percentages of the answers.
Results
All results are presented as the percentage of the total number of responses received per question. Results are presented with all affiliations combined. In addition, we show the percentage of the 887 scientists who were asked that responded to each question (i.e., the response rate).
Study Survey Demographics
Scientists (n=887) from various fields of expertise ( Fig. 1A ) and geographic locations ( Fig. 1B) were invited to participate in the survey and 85 (or 10%) responded. Of the 85 responders, a preponderance was from Europe (46%), followed by North America (38%) and Asia (17%).
Responders originated from diverse business organizations ( Fig. 1C ) and company sizes ( Fig.   1D ) with 57% employed at companies with >1000 employees. Thus, one cannot exclude the potential that multiple responders from the same organization may have contributed to this survey (an issue that was not quantified in the responses) despite a request that only one response be provided from the same organization. Most responders were employed by pharmaceutical companies, followed by CROs and biopharmaceutical companies (Fig. 1C ). The survey identified many interesting facts including the primary therapeutic areas that were pursued by the various companies ( Fig 1E) . Oncology (74%) and neurology (68%) were the therapeutic indications frequently targeted for drug development followed by cardiovascular Authier et al 2016 JPTM 2/16/2017 5 (62%), inflammation (58%), metabolic diseases (51%), infectious disease (39%) and lastly, rare/orphan diseases (36%). When asked, 60% of responders were involved with the design, conduct, interpretation, or review of in silico assays ( Fig. 1F ) and the response rate increased to 87% for those involved in the conduct of in vitro ion channel assays ( Fig. 1G ). A majority (61%) of responders reported that their company developed small molecules (new chemical entities; NCE) while 27% of responders worked for institutions developing large molecules/biologics.
Approaches that address Proarrhythmia & CiPA Related Drug Testing: Survey
Results
The most frequent (75%) nonclinical approach used to address proarrhythmia issues by responders was to conduct a battery of in vitro (i.e., binding and ion channel electrophysiology studies, etc.) and in vivo CV safety pharmacology assays to screen drug candidates and establish a risk profile during the drug discovery phase of development ( When asked which assays were used in the last 5 years to assess cardiac/cardiovascular effects, the responses were analyzed in terms of those in vitro assays with potential application to CiPA method implementation and included cell lines stably expressing ion channels for determination of drug block potency (89%), ion channel binding assays (57%), human stem cellderived or induced pluripotent stem cell cardiomyocytes (iPSC-CM) (46%) and hERG channel trafficking (42%) and isolated tissue bath preparations (41%). Those cardiac/cardiovascular assays/models currently used to evaluate cardiac safety include ECG recordings using implanted telemetry systems (88%) followed by jacketed external telemetry (JET) (62%), anesthetized animal models (53%), cardiac action potential recordings using e.g., Purkinje fibers (51%), isolated Langendorff hearts (38%) and isolated cardiac wedge preparations (18%), with both proarrhythmia animal models and Zebrafish assays used by 12% of responders (Table 2) .
Conduct of In Silico Assays
One third of responders frequently used in silico studies to evaluate drug effects on I Kr ('hERG' assays) while 35% of them had never used in silico studies for this purpose (Table 3 ). Only 15% of responders reported frequently using in silico studies to evaluate drug effects on the cardiac Authier et al 2016 JPTM 2/16/2017 6 action potential and 39% of responders had never used in silico studies at their company. Noncardiac drug safety evaluations that were reportedly using in silico models included genetic toxicity evaluations and the study of effects on other cardiac ion channels. When in silico studies were used, assays were reported to be conducted as part of the early discovery safety study assessment by a large proportion of responders (43%); however, 44% report that in silico modeling is not used at their respective companies (Table 4 , panel A).
In Vitro Ion Channel Electrophysiology Assays
When asked to describe the timing of conduct of in vitro ion channel electrophysiology assays, most responders (80%) reported using in vitro assays during conduct of early safety frontloading (or discovery) phase of investigation before complete nonclinical data was obtained ( Table 4 , panel B). In vitro assays were most frequently used to assess QT prolongation (95%). Cardiac Ca 2+ (82%) and Na + channel blockade (82%), QT shortening (53%) and QRS prolongation (53%) were also reported as common applications of in vitro assays (Fig. 2 ). Only 33% of responders reported using in vitro assays to assess positive or negative cardiac inotropic effects, the remainder likely did not conduct such assessments. When establishing the IC 50 values for ion channel blockade most responders (37%) reported using four (4) test article concentrations ( Fig. 3) . A minority (36/85 or 42%) reported calculating confidence intervals for the IC 50 values determined using in vitro ion channel assays ( Fig. 4 ). Many responders (59%)
reported that their company had abandoned a pharmacophore due to an inability to eliminate the potential for I Kr blockade (Fig. 5 ). However, of the 59% reporting only 10% frequently report abandoning a pharmacophore due to an inability to eliminate hERG channel blockade.
Interestingly, 22% state that although hERG channel block may not be eliminated chemically they have not discontinued development of the pharmacophore. A majority (82%) also reported that in vitro ion channel testing procedures include the use of a positive control in each study (Table 5) with the assays performed at either room temperature (71%) or at physiological temperature (58%). Washout data was obtained by a minority of responders (43%). Automated (75%) or manual (71%) patch clamp systems were used by a similar proportion of responders with 48% conducting in vitro assays to Good Laboratory Practice (GLP).
As expected, I Kr /Kv11.1 (91%), I Ca,L /Cav1.2 (80%), I Na /Nav1.5 (77%) and I Ks /Kv7.1 (53%) were the most frequently interrogated cardiac ion channels when used in stably expressed cell lines (Table 6 ). Although not as frequent, I Kur /Kv1.5 (29%), I to,f /Kv4.3 (22%), I K1 /Kir2.1-2.3 (22%) and I f /HCN4 (20%) were also evaluated. Drugs used as positive controls that were most frequently tested in the validation/qualification of each cardiac ion channel assay included E-4031 (65%), 7 verapamil (62%), nifedipine (59%), dofetilide (59%), cisapride (56%), flecainide (53%) and terfenadine (52%) ( Table 7) . Note that because of survey responders being from both the pharmaceutical industry and CRO's, some compounds referenced in this table may have been   reported by both if such studies were contracted out and conducted by CRO study director scientists. Similarly, positive control drugs that were used frequently for cardiac ion channel studies in order to interpret and compare the IC 50 values obtained for NCE's also included a range of K + , Ca 2+ and Na + channel blockers such as E-4031 (79%), verapamil (72%), terfenadine (69%), dofetilide (67%), nifedipine (64%), flecainide (62%), cisapride (58%), quinidine (57%) and sotalol (55%) ( Table 8 ). One third of responders (34%) estimated the variability (i.e., the range from lowest to highest value obtained) in IC 50 values to be <25% while 22% indicated that outcome variability was not formally evaluated and 24% did not know the level of variability of their assays (Table 9 ). A majority of responders (66%) used a supramaximal concentration of their positive control drug when conducting an in vitro ion channel study in order to determine whether the assay responded appropriately whereas half (49%) used a concentration of the positive control in the range of its IC 50 value to assess sensitivity (Table 10 ). Most (79%) always used the same positive control drug in their ion channel assay whereas a minority selected positive controls to include a comparator/similar drug to the compound being tested (22%) while only 13% used a positive control drug based on the chemistry of the compound being tested. Only 7% used a positive control based on the therapeutic indication of the compound to test (7%) ( Table 11 ).
Arrhythmias
When asked whether drug-induced arrhythmias were encountered in the conduct of non-clinical studies only 22-44% of responders provided some indication of their observation (Table 12 ). Of the types of drug-induced arrhythmias queried, PVCs were most frequently reported for the standard CV safety model using dogs (80%); however, PVCs were also observed in NHP (59%), rabbit (29%) and guinea pigs (17%) ( Table 12 ). Ventricular tachycardia was most frequently observed in dogs (79%) followed by NHP (58%) and rabbits (39%). AVB was another common arrhythmia reported (77%) in drug studies involving the use of dogs.
Responders also observed drug-induced ventricular fibrillation most frequently in dogs (55%) and NHP (55%). Note that the dog and NHP are the most frequently used non-clinical safety pharmacology species thus there is a likely increased propensity for observations of various arrhythmia's developing when NCE's are tested in these species. 
Human stem cells derived or iPSC cardiomyocytes
Human stem cell derived or iPSC-CM were considered by most responders as a valuable addition to the spectrum of proarrhythmia screening assays (75%); however, only 26% considered such assays as an economically valuable addition to the safety study arsenal of non-clinical studies (Table 13 ). While 21% of responders considered human stem cell derived or iPSC-CM representative of adult cardiomyocytes and provide reliable data as a nonclinical safety assay, an equal number (19%) considered that these cells expressed relevant endogenous cardiac ion channels in culture to provide reliable data. Remarkably, only 17% of responders consider that human stem cell derived or iPSC-CM could replace cell lines that stably express human cardiac ion channels.
When responders were asked to estimate the predictivity for clinical responses (e.g., study
findings from conduct of the Thorough QT (TQT) study) of the nonclinical safety assays used in the integrated risk assessment, only 21% selected 75-90% while only 15% selected >90% (Table 14) . 21% of respondents do not know the estimated predictivity for clinical responses of the non-clinical safety assays used while 40% did not formally evaluate predictivity.
CiPA
Currently most responders view the ion channel portion of CiPA as a screening tool (56%) that is likely to be used primarily at the lead development stage (42%) of the drug development spectrum. Only 34% would consider including it as a component of the first-in-human (FIH) regulatory submission package (Table 15 ) while 17% consider the CiPA ion channel assay as a requirement strictly indicated by the regulatory agencies (i.e., it currently would be only conducted as a check box exercise). Note, however, that 13% of responders currently do not know how they would anticipate using the CiPA ion channel assays in drug development.
Discussion
The present survey aimed to identify current strategies that are used by those in the pharmaceutical industry, in particular safety pharmacologists, for non-clinical safety testing as they relate to proarrhythmia liability assessment. In addition, a focus was placed on assays that are currently under evaluation within the CiPA initiative. The geographic region that contributed the largest number of responses was Europe. This proportion contrasts with prior SPS surveys (Friedrichs et al., 2005; Lindgren et al., 2008; , Authier, 2013 for which North America was the predominant region. The percentage of responders involved in the development of small molecules reached 61%, which likely reflects a selection bias whereby A pre-established battery of assays to screen drug candidates was used by most (75%) responders. This is perhaps somewhat surprising given that the common perception within SP testing is that approaches are taken in which studies are tailored with regard to indication, risk/benefit considerations and other factors such as whether the molecule is a biological or NCE . However, as has been pointed out previously, in the case of NCEs, potency in these assays has little to do with therapeutic class (Redfern et al., 2003) . Amongst available assays, cell lines with stably expressed ion channels and telemetry acquired ECG were used by most (89% and 88% of responders, respectively). Other assays had varying degrees of utilization which likely reflects historical practices within each organization, the perceived proarrhythmic risk of the drug candidate (i.e., science driven selection of proarrhythmia assays) based upon therapeutic area and the validation data available to support the added value of a given test as part of the overall risk assessment. As expected, given that
CiPA is an emerging drug safety screening paradigm that is not yet fully validated, application of in silico assessment was not widely implemented. At present, in silico assays were most frequently reported (43%) to be used early in drug discovery. When in vitro assays were used, screening for I Kr block remained the most frequent application followed by assessment of the effects on cardiac action potentials Valentin 2010; Valentin et al. 2010 ).
This likely reflects the 'hERG-centric' approach to proarrhythmia testing which has prevailed within SP for well over a decade, consistent with issuance of ICH S7B (US FDA, 2005) . As shown in Table 4B , in vitro assays, when used, were conducted early in drug discovery (i.e., frontloaded) during drug development. In vitro assays were predominantly used to assess potential effects of drugs on cardiac cellular electrophysiology processes (Table 2) .
A majority (59%) reported that their company had abandoned at least one pharmacophore (or potential 'toxicophore') based on data obtained from assays characterizing drug-mediated blockade of I Kr . This is an interesting finding that supports the rationale for the CiPA paradigm, originally proposed as the next logical step in drug proarrhythmia testing (Gintant et al., 2015; ). As such, efforts are underway to provide a clear roadmap in the evaluation of the cardiac ion channel assays involved and provide oversight with regard to validation of a standardized testing strategy (Sager et al., 2014; Colatsky et al. 2016; Crumb et al., 2016) . ion channel assays at room temperature, which could reflect the current inability of some automated patch clamp systems to control experimental temperature. Potential differences in the predictive value of assays conducted at physiological or room temperatures are not fully characterized (Zhou et al., 1998) and the optimal testing conditions remain an open agenda item as CiPA efforts progress.
Testing for drug effects on a panel of cardiac ion channels is required for a mechanistic prediction of the net effect of a drug on the ventricular action potential. The various cardiac ion channels were assessed in the following order of importance by responders:
K v 11.1>Ca v 1.2>Na v 1.5>K v 7.1>K v 1.5>K v 4.3>K ir 2.1-2.3. These results suggest that the strategy to evaluate the proarrhythmic risk of an NCE can differ significantly amongst safety pharmacologists. The well characterized contribution of individual ionic currents to the genesis of the ventricular action potential has yet to produce a validated, integrated in silico proarrhythmia liability assay.
Understanding the need to properly evaluate the proarrhythmic risk of a NCE is imperative to safety pharmacologists. It should be recognized that the incidence of nearly all arrhythmia types (apart from heritable channelopathy related arrhythmias) increases with age (Chow et al., 2012) . Arrhythmias are the most common cause of sudden cardiac death (SCD) in patients with hypertrophic or dilated cardiomyopathy (O'Mahony et al., 2013; Wu et al., 1999) and ischaemic heart disease (Huikuri et al., 2001) . Concurrent to this, it needs to be recognized that the use of prescription drugs also increases with age (Qato et al., 2016) which positions drug-induced arrhythmia as a serious safety concern. However, the susceptibility of the young animal population to spontaneous arrhythmia (Gauvin et al., 2009) notably differs from that observed in an older patient population, albeit limited studies are conducted to characterize spontaneous arrhythmias in standard laboratory animals of normal health at any age. Rather, such studies, primarily academic in nature, involve development of arrhythmias by simulating pathology, e.g., by coronary artery ligation (Cheung et al., 1993; Hagerty et al., 1996) . Unfortunately, the sensitivity of pre-clinical safety models to drug-induced arrhythmia development has been erroneously perceived to be lower than the sensitivity in the human population placing additional pressure on development of alternate arrhythmia risk assessment methods. This is easily illustrated by the fact that the non-sedating antihistamine, terfenadine, which is regarded as a positive control for torsades de pointes proarrhythmia assessment, in fact elicited torsades de
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Therefore the imperative to evolve a more predictive approach to proarrhythmia liability testing appears correct; however, the justification that animal models used in the assessment for druginduced proarrhythmia activity lack sensitivity is flawed. A lack of sensitivity in models is appropriate given the low risk of proarrhythmia in humans for all drugs, even drugs with established liability. The safety pharmacologist should recognize that the most important part of the problem is one of preclinical proarrhythmia bioassay sensitivity and specificity; particularly the ability to detect liability with a feasibly small number of experimental preparations. We make this point because the CiPA initiative, commendable though it is, may be attempting to solve the problem of detecting low risk liability by collecting multiple readouts all of which lack specificitybecause risk is low, not because the magical formula of multiple target effect profile has not yet been identified (Authier et al., 2010) . This would all be inconsequential were it not for the fact that proarrhythmia (especially production of torsades de pointes) can be lethal.
The current survey identified PVCs as the most frequently reported arrhythmia type, especially in large animal species used in the conduct of standard SP studies. However, the survey did not explore the subtype of arrhythmia specifically defined as a PVC. However, because these arrhythmias are commonly observed with a prevalence estimated between 1-4% in humans (Kennedy et al., 1985) and because it is conceivable that they may respond differently to drugs, it is usually prudent to define their nature (Curtis et al., 2013) . More serious ventricular arrhythmias including ventricular tachycardia and ventricular fibrillation were reported in all species, especially in dogs, likely also due to their frequent use in cardiac safety studies (Lindgren et al., 2008) . When compared to other species, the proportion of responders that observed AVB in dogs was much higher than that in other species. While most responders considered that human stem cell derived or iPSC cardiomyocytes were a valuable addition to the overall proarrhythmia screening assay, potential limitations to their use appeared to include reliability of the cells to represent adult cardiomyocyte phenotypes, cardiac ion channel expression stability, and financial considerations. It appears that a certain apprehension within the SP community remains in the implementation of this assay beyond validation.
A large proportion of responders (40%) acknowledged that the actual predictive value of nonclinical safety assays for the clinical TQT response has not been formally evaluated.
However, publications have addressed the predictive value of QTc measurements in beagle dogs, if not for the TQT outcome, then for QT effects in humans. Ollerstam et al. (2006) explored the PK-PD relationships for QTc prolongation by dofetilide in dogs and humans. This approach has been extended to a larger number of compounds (Parkinson et al., 2013 that identified both human and non-rodent animal studies that assessed QT signal concordance between species, based on 40 marketed drugs. The study primarily found that QT interval data derived from relevant non-rodent models had a 90% chance of predicting QT findings in humans. However, the perception revealed by this survey highlights the need for CiPA to assemble all the available published data on concordance between nonclinical (in silico, in vitro and in vivo) assays/models in order to critically evaluate current non-clinical assays, evaluate drugs with broad ion channel blocking characteristics and derive data-driven recommendations for use.
The anticipated utilization of the CiPA assay differed between responders as some considered it would be better used as a screening tool (56%), while others considered its implementation at the lead stage of drug development (42%) or as part of the FIH package (34%). As the initiative progresses, it is hoped that the CiPA assay is able to impact drug development efforts and better establish a framework to guide proarrhythmia risk assessment.
To this effect it is worth mentioning that during the ICH Assembly meeting held in Jacksonville, FL on December 9-10, 2015, the decision was taken to reopen the ICH S7B and E14
Discussion Group with the objective to review emerging data that may influence the content of both ICH S7B and E14 in the future (Anonymous, 2016).
Survey limitations included the potential participation of several employees from the same organization. The response rate (i.e. 10%) was lower than other recent industry surveys undertaken by the SPS but was comparable to the previous survey on the same topic. The lower response rate may be explained by the specialized nature of CiPA related assays.
Conclusion
Proarrhythmia liability assessment in drug development presently includes study types consistent with CiPA. It is anticipated that CiPA will develop into a workable solution to the concern that proarrhythmia liability testing remains suboptimal. The main anticipated value, however, is to avoid falsely identifying drugs as unsafe that in fact are safe in humans (Wallis, 2010; Gintant et al., 2016) , although examples of such drugs in current use are limited to verapamil, ranolazine and alfuzosin. This is rather different from developing a more sensitive integrated approach for detecting proarrhythmia liability. It is important the two are not confused.
The present survey indicates that current practice has yet to assimilate this disconnect. Tables   Table 1 Nonclinical approaches used to address proarrhythmia issues What best describes the nonclinical approach used to address proarrhythmia issues in your company?* Answer Options Response Percent
Response Count
Conduct a battery of in vitro (i.e., binding studies, ion channel studies, etc.), and in vivo CV safety pharmacology assays to screen drug candidates and establish risk during drug discovery 75% 58
Conduct "fit-for-purpose" nonclinical safety pharmacology tests based on an integration of observations derived from chemistry (SAR), Toxicology findings and other scientific considerations (e.g., drug indication, drug class, pharmacology, PK/PD etc.)
31% 24
Perform safety testing based on GLP findings from safety pharmacology and toxicology studies only 20% 15 I do not know 4% 3
* Responders selected all that applied. In silico studies are used to evaluate other effects (Please specify) -Genetic toxicity (6) -Effects on other CV ion channels (2) -Brain penetration (2) -Others (9) 19 * Responders selected all that applied.
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ACCEPTED MANUSCRIPT Authier et al 2016 JPTM 2/16/2017 30 In silico assays are conducted early in drug discovery 43% 32 In silico assays are conducted before any nonclinical data is obtained 17% 13
In silico assays are conducted during drug development (i.e., after compound nomination) 13% 10
In silico assays are conducted during nonclinical GLP studies 12% 9
In silico assays are conducted after Phase 1 clinical trials 1% 1
Panel B
What best describes the timing of in vitro ion channel electrophysiology assays conducted by your company?*
Answer Options Response Percent
Response Count
In vitro electrophysiology assays are not used by my company 7% 5 In vitro assays are conducted early in drug discovery/before nonclinical data is obtained 80% 61
In vitro assays are conducted during drug development (i.e. after compound nomination/selection) 40% 30
In vitro assays are conducted during nonclinical GLP studies 30% 23
In vitro assays are conducted after Phase 1 clinical trials 3% 2 * Responders selected all that applied.
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To determine assay sensitivity by using a concentration of the positive control that is similar to its IC 50 value 49% 35
A positive control drug is not used in ion channel assays 3% 2 * Responders selected all that applied.
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Answer Options Response Percent
Response Count
We always include the same positive control drugs 79% 60 We select positive control drugs based on chemistry of the compound to test 13% 10 We select positive controls based on the therapeutic indication of the compound to test 7% 5 We select positive controls to include comparator/similar drugs to the compound to test 22% 17 * Responders selected all that applied.
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